We will probably know only after OLE is done, if there is going to be a BTD for PDD.
I do not know if the additional data we have been waiting for all these months, is going to be presented along with any OLE data - if that is possible(depending on FDA's input).
Was the initial trial duration for PDD (14 week study)long enough to generate a signal strong enough to get the FDA interested? or will the extended OLE provide solid evidence/confirmation?
Market Data 
Markets 
AI
